Who
ARE WE?
AELMHU is a non-profit association, established in 2011 by a group of pharmaceutical and biotechnology companies, with a strong commitment to research, develop and commercialise innovative therapies to improve the quality of life of patients suffering from rare and ultra-rare diseases.
Our
MISSION
To contribute to improving the health and quality of life of people affected by rare diseases, giving visibility to the pathologies and highlighting research and treatments for them.
What do
YOU DO?
WE COLLABORATE WITH ORGANISATIONS
patients, public administrations and other stakeholders, with the aim of contributing our knowledge and experience in the treatment of rare diseases.
WE TRAIN AND INFORM
on the value of orphan and ultra-orphan drugs for the treatment of these pathologies.
WE GIVE VISIBILITY
to the special characteristics of rare and ultra-rare diseases
WE JOIN FORCES
and we support R&D to bring new orphan drugs to the market.
Bodies of GOVERNMENT
The supreme governing body of AELMHU is the General Assembly. This body is composed of all members in their own right and on an equal footing.
The association also has a Board of Directors, which is responsible for managing and representing the association.
The current members of the Board of Directors are:
Mª JOSÉ SÁNCHEZ
President
JOSÉ LUIS MORENO
Vice-President
BEATRIZ PERALES
Secretary and member
SERGIO BULLÓN
Treasurer and member
The AELMHU technical team supporting the Board of Directors is led by:
MARIAN CORRAL
Executive Director
MEMBERS
AELMHU is made up of small and medium-sized pharmaceutical and biotechnology companies. The common denominator of all of them is their strong commitment to research into rare diseases and the search for innovative therapies to improve the quality of life of patients suffering from these pathologies.
Become a partner
Do you want to join AELMHU?
